ADCT Kacepetan wutah bathi saben saham ing taun lumaku ADC Pharma

Simbol resmi perusahaan ADC Pharma (ADCT)

The diversification of hematologic malignancy treatment programs in the US and Europe creates significant potential, as confirmed by the year-over-year EPS comparison for ADC Therapeutics (ADCT). Premium pricing driven by patents and stable demand for Zynlonta minimize operational risks. The current value of the indicator is 37.90, allowing for an objective assessment of real business dynamics and the avoidance of capital drawdown.

ADCT - Wutah bathi ing taun lumaku ADC Therapeutics SA ing rentang 04.07.2022 - 16.11.2026

Rincian metrik keuangan lan pasar ADC Therapeutics S.A. (ADCT)

- nilai saham lan prakiraan konsensus rega:
Ringkesan analisis perusahaan:ADC Therapeutics (ADCT)
Produk merek ADC Therapeutics SA

Assessing asset reliability begins with analyzing the growth rates of net income per share, which reveals the actual efficiency of capital management. This calculation, reflecting the annual EPS growth in the context of Zynlonta's expansion in lymphoma therapy markets, determines the speed of innovation monetization, as clearly demonstrated by the annual net income per share dynamics for ADC Therapeutics (ADCT) on the GURU.Markets service.